Evaluation of a Single Dose of Inhaled Sargramostim in Patients With Autoimmune Pulmonary Alveolar Proteinosis
Phase of Trial: Phase I
Latest Information Update: 16 Oct 2017
At a glance
- Drugs Sargramostim (Primary)
- Indications Pulmonary alveolar proteinosis
- Focus Adverse reactions
- Acronyms PharmPAP
- 11 Oct 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Mar 2018.
- 11 Oct 2017 Status changed from not yet recruiting to recruiting.
- 31 Jul 2017 Planned initiation date changed from 15 Jul 2017 to 1 Sep 2017.